ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

UroViu Receives CE Certification of Its Wi-Fi Enabled Cystoscope and Hysteroscope Product Portfolio

UroViu Corporation announced today that it has received CE certification for its cystoscope and hysteroscope product portfolio. This includes the reusable UV5000w Wi-Fi Handle and the disposable Hystero-V, Uro-V, and Uro-GHD endoscopes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105615011/en/

"This CE certification is a significant milestone for UroViu and will enable us to offer our versatile, portable, and environmentally friendly endoscopy portfolio to patients in all regions that accept the CE Marking worldwide," said Bruce OuYang, Ph.D., CEO. "The UV5000w platform represents a major advancement in endoscopy, allowing clinicians to maintain their line of sight during procedures while providing secure wireless connectivity and simultaneous external display for patient and additional clinician viewing.”

The UroViu portfolio has been widely adopted across various segments of the U.S. Urology and UroGynecology market, including private practices, Ambulatory Surgical Centers (ASCs), academic institutions, VA, and DOD healthcare facilities. UroViu products offer several unique features ideal for offices and outpatient clinics:

  • Self-Contained, Cordless, Untethered Design: This design minimizes environmental impact and the carbon footprint of disposable products by eliminating the need for peripherals. The profile and weight of all our disposable products are half to a third compared to similar products on the market.
  • Portability and Simplicity: The UV5000w transforms any room into a procedure room, allowing for schedule expansion and creating workflow efficiencies that benefit both practices and patients.
  • Versatile Platform: The UV400 platform facilitates the rapid addition of single-use cannulas optimized for a variety of indications, providing flexibility for healthcare providers without requiring investment in additional reusable devices.

Data presented at recent meetings of the EAU and AUA demonstrate the clinical value and efficiency of UroViu’s portfolio for cystoscopy procedures, including diagnosis, cancer surveillance, and other simple therapeutic procedures.

For more information on international distribution outside of the USA or to schedule a hands-on demonstration, please contact UroViu's sales representatives or customer service as listed on our website: https://www.uroviu.com.

UroViu Corp, based in Los Altos, California, develops, manufactures, and commercializes advanced single-use endoscopic visualization solutions worldwide. The company pioneered the world's most portable cystoscopy platform that is always ready, eliminating the need for reprocessing, capital equipment, servicing, and advance scheduling. UroViu's mission is to simplify workflows and expand access to high-quality endoscopy by integrating cutting-edge technologies, including edge AI and robotics.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.